Source:http://linkedlifedata.com/resource/pubmed/id/19037994
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2009-1-8
|
pubmed:abstractText |
Non-myeloablative allogeneic stem cell transplantation is an option for the treatment of hematological malignancies as well as solid tumors. We recently proposed a cyclophosphamide-using non-myeloablative cell therapy in which donor lymphocytes infusion (DLI) was carried out after tolerance induction to donor cells. In this study, we tested the possibility that the cyclophosphamide-using cell therapy could be augmented by pre-immunization of donors before DLI. We initially assessed whether or not the cyclophosphamide-using cell therapy could also show antitumor effect against subcutaneously established colon 26 carcinoma. As a tumor antigen-derived peptide for colon 26, we used AH1, an immunodominant H-2Ld-binding peptide derived from the envelope protein (gp70) of an endogenous murine leukemia virus. The cyclophosphamide-using cell therapy with the DLI from donors which were pre-immunized with the AH1 peptide was compared with that from non-immunized mice. The cyclophosphamide-using cell therapy significantly suppressed subcutaneously established colon 26 carcinoma, and the tumor-rejected mice acquired the tumor-specific protective immunity. When combined with the DLI from donors that were immunized with AH1, antitumor effect of the cyclophosphamide-using cell therapy was significantly augmented. The DLI from tumor peptide-immunized donors showed no influence on donor chimerism and bodyweight of the treated mice, indicating no increased risk of graft-versus-host disease. Tumor-specific cytotoxic T lymphocytes could be generated from tumor-rejected mice. Our results indicate that the cyclophosphamide-using non-myeloablative cell therapy with the DLI from tumor peptide-immunized donors is a useful protocol to augment graft-versus-tumor effect without exacerbation of graft-versus-host disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1349-7006
|
pubmed:author |
pubmed-author:EtoMasatoshiM,
pubmed-author:HamaguchiMasumitsuM,
pubmed-author:HaradaMamoruM,
pubmed-author:HaranoMasahikoM,
pubmed-author:KamiryoYoriyukiY,
pubmed-author:NaitoSeijiS,
pubmed-author:TakeuchiArioA,
pubmed-author:TatsugamiKatsunoriK,
pubmed-author:TeshimaTakanoriT,
pubmed-author:YoshikaiYasunobuY
|
pubmed:issnType |
Electronic
|
pubmed:volume |
100
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
138-43
|
pubmed:meshHeading |
pubmed-meshheading:19037994-Animals,
pubmed-meshheading:19037994-Antigens, Neoplasm,
pubmed-meshheading:19037994-Cyclophosphamide,
pubmed-meshheading:19037994-Female,
pubmed-meshheading:19037994-Graft vs Host Disease,
pubmed-meshheading:19037994-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19037994-Immunization,
pubmed-meshheading:19037994-Lymphocyte Transfusion,
pubmed-meshheading:19037994-Mice,
pubmed-meshheading:19037994-Mice, Inbred BALB C,
pubmed-meshheading:19037994-Mice, Inbred DBA,
pubmed-meshheading:19037994-Neoplasms, Experimental,
pubmed-meshheading:19037994-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:19037994-Transplantation, Homologous
|
pubmed:year |
2009
|
pubmed:articleTitle |
Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation.
|
pubmed:affiliation |
Department of Urology, Graduate School of Medical Sciences, Kyushu University, and Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|